

Japan's Astellas Pharma partners with Mogrify to address sensorineural hearing loss

06 July 2022 | News

Announce collaboration to conduct research on in vivo regenerative medicine approaches



UK-based Mogrify Limited, a biopharmaceutical company transforming the lives of patients through a novel class of *in vivo* reprogramming therapies, and Japan's [Astellas Pharma](#), a leader in regenerative medicine, have executed a collaborative research agreement on *in vivo* regenerative medicine approaches to address sensorineural hearing loss.

Utilizing Mogrify's proprietary direct cellular reprogramming platform, the collaboration will seek to identify novel combinations of transcription factors involved in cell differentiation to generate new cochlear hair cells.

As part of the collaboration, Astellas Gene Therapies, a division of Astellas, is covering the research cost of the work as well as contributing its expertise in adeno-associated virus (AAV) based genetic medicine and translational capabilities to complete experiments in pre-clinical models.

Mogrify will exploit its bioinformatic platform, screening and validation process to characterize potential therapeutic factors.

An estimated 1.57 billion people globally suffer from hearing loss, and US data suggests that over 10% have severe to profound sensorineural hearing loss in at least one ear. This degree of hearing loss significantly reduces quality of life and, with no drug treatments currently available, represents a large unmet need.